Sarepta Therapeutics recently refinanced a significant portion of its debt, extending maturities and enhancing financial ...

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Alnylam is making a $250 million investment in its Massachusetts manufacturing facility. The investment comes as the company begins to expand beyond rare disease treatments into more common conditions ...

Citi analyst Filippo Falorni raised the firm’s price target on PepsiCo (PEP) to $170 from $165 and keeps a Buy rating on the shares. The firm ...

Deutsche Bank analyst Stephen Powers maintained a Buy rating on PepsiCo yesterday. The company’s shares closed yesterday at $151.22.

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...